Improved engraftment rates of AML samples have been achieved using NSG‐SGM3 (NSG humanized with SCF, GM‐CSF, and IL‐3) including cases where cells were from intermediate‐risk AML patients. The gene discussed is CSF2; the disease is acute myeloid leukemia.